Patents by Inventor Gil Benedek

Gil Benedek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant CD74 polypeptides
    Patent number: 10689446
    Abstract: Disclosed are recombinant CD74 polypeptides mutated relative to the naturally occurring CD74 polypeptides with improved properties such as binding of CD74 ligands such as MIF and RTL1000 as well as polynucleotides that encode the polypeptides, expression vectors comprising the polynucleotides, bacteria that include the expression vectors, and methods of making the recombinant polypeptides.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: June 23, 2020
    Assignees: OREGON HEALTH & SCIENCE UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Roberto Meza-Romero, Gil Benedek, Arthur A. Vandenbark
  • Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
    Patent number: 10525101
    Abstract: Recombinant polypeptides, pharmaceutical compositions comprising recombinant polypeptides, and methods of treating autoimmune and/or inflammatory diseases using the pharmaceutical compositions are disclosed. The polypeptides are based upon the trimerization and/or MIF binding domains of CD74.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: January 7, 2020
    Assignees: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Arthur A. Vandenbark, Gil Benedek, Roberto Meza-Romero
  • Recombinant polypeptides comprising MHC class II ?1 domains
    Patent number: 10316075
    Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: June 11, 2019
    Assignees: Oregon Health & Science University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
  • RECOMBINANT CD74 POLYPEPTIDES
    Publication number: 20170369577
    Abstract: Disclosed are recombinant CD74 polypeptides mutated relative to the naturally occurring CD74 polypeptides with improved properties such as binding of CD74 ligands such as MIF and RTL1000 as well as polynucleotides that encode the polypeptides, expression vectors comprising the polynucleotides, bacteria that include the expression vectors, and methods of making the recombinant polypeptides.
    Type: Application
    Filed: June 21, 2017
    Publication date: December 28, 2017
    Applicants: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Roberto Meza-Romero, Gil Benedek, Arthur A. Vandenbark
  • COMPOUNDS THAT BIND MACROPHAGE MIGRATION INHIBITORY FACTOR
    Publication number: 20170114117
    Abstract: Recombinant polypeptides, pharmaceutical compositions comprising recombinant polypeptides, and methods of treating autoimmune and/or inflammatory diseases using the pharmaceutical compositions are disclosed. The polypeptides are based upon the trimerization and/or MIF binding domains of CD74.
    Type: Application
    Filed: October 21, 2016
    Publication date: April 27, 2017
    Applicants: Oregon Health & Science University, The United States Government as represented by The Department of Veterans Affairs
    Inventors: Arthur A. Vandenbark, Gil Benedek, Roberto Meza-Romero
  • RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II a1 DOMAINS
    Publication number: 20150098956
    Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
  • PARTIAL MHC CONSTRUCTS AND METHODS OF USE
    Publication number: 20150044245
    Abstract: Disclosed herein are isolated major histocompatibility complex (MHC) class II ?1 domain polypeptides and methods of use. In some embodiments, the isolated polypeptide comprises or consists of an MHC class II ?1 domain polypeptide (or portion thereof) and does not include an MHC class II ?2, ?1, or ?2 domain. The disclosed MHC class II ?1 domain polypeptides are of use in treating or inhibiting disorders in a subject, such as inflammatory and/or autoimmune disorders. Also disclosed are methods of evaluating efficacy of treatment or optimizing treatment of a subject with a polypeptide including an MHC class II ?1 domain polypeptide (or portion thereof) or a polypeptide including an MHC class II ?1 domain and ?1 domain (such as a ?1?1 RTL).
    Type: Application
    Filed: January 4, 2013
    Publication date: February 12, 2015
    Inventors: Arthur A. Vandenbark, Gregory G. Burrows, Roberto Meza-Romero, Gil Benedek, Shayne Andrew, Jeffery Mooney